Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents.

Area of Science:

• Genetics and Molecular Biology
• Connective Tissue Disorders
• Fibrotic Diseases

Background:

• Myhre Syndrome (MYHRS) is a rare, multisystem connective tissue disorder.
• It stems from gain-of-function variants in the SMAD4 gene, crucial for TGF-β signaling and extracellular matrix.
• MYHRS presents a progressive fibrotic phenotype impacting skeletal, cardiovascular, respiratory, and integumentary systems.

Purpose of the Study:

• To review the current understanding of Myhre Syndrome.
• To explore potential future therapeutic strategies for MYHRS.
• To identify unmet needs in clinical and biochemical endpoints for therapy development.

Main Methods:

• Literature review of Myhre Syndrome.
• Discussion of potential therapeutic targets including TGF-β inhibitors and anti-fibrotic drugs.
• Analysis of current research gaps and future directions.

Main Results:

• MYHRS is characterized by short stature, joint contractures, cardiac defects, subglottic stenosis, and skin thickening.
• Neurodevelopmental disorders, such as autism spectrum disorder, can also occur.
• Significant phenotypic variability exists among individuals with MYHRS despite recurrent mutations.

Conclusions:

• Current treatment for MYHRS is purely symptomatic, with no disease-modifying therapies available.
• Investigational therapies include TGF-β inhibitors, anti-fibrotic agents, and gene editing.
• Further research is needed to define clinical and biochemical endpoints for effective therapy evaluation.